PARD3-ALK: A novel ALK fusion gene identified in a patient with lung adenocarcinoma

被引：0
|
作者：
Yang, Liangwei [1 ,2 ]
Zhao, Weidi [3 ]
Zhu, Huangkai [1 ]
Li, Xi [4 ]
Zhao, Guofang [1 ,2 ]
机构：
[1] Univ Chinese Acad Sci, Hwa Mei Hosp, Dept Cardiothorac Surg, Ningbo Hosp 2, Ningbo 315010, Peoples R China
[2] Univ Chinese Acad Sci, Ningbo Inst Life & Hlth Ind, Ningbo, Peoples R China
[3] Ningbo Univ, Med Sch, Clin Dept, Ningbo 315211, Peoples R China
[4] Burning Rock Biotech, Guangzhou 510300, Guangdong, Peoples R China
来源：
LUNG CANCER | 2021年 / 154卷
关键词：
D O I：
10.1016/j.lungcan.2021.02.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：219 / 220
页数：2
相关论文
共 50 条
  • [21] Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report
    Zhou, Huamiao
    Xu, Binyue
    Xu, Jili
    Zhu, Guomeng
    Guo, Yong
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [22] Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report
    Wu, Xueqian
    Wang, Weiya
    Zou, Bingwen
    Li, Yanying
    Yang, Xiaojuan
    Liu, Ning
    Ma, Qizhi
    Zhang, Xiaoxuan
    Wang, Yongsheng
    Li, Dan
    [J]. THORACIC CANCER, 2020, 11 (06) : 1695 - 1698
  • [23] A novel GHR-ALK fusion gene in a patient with metastatic lung adenocarcinoma and its response to crizotinib: a case report
    Pan, Xue
    Zhong, Anyuan
    Xing, Yufei
    Li, Xi
    Du, Haiwei
    Shi, Minhua
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2021, 49 (09)
  • [24] Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib
    Luo, Jing
    Gu, Dejian
    Lu, Huasong
    Liu, Si
    Kong, Jinliang
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (12) : E266 - E268
  • [25] Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma
    He, Zhen
    Wu, Xuan
    Ma, Shuxiang
    Zhang, Cuicui
    Zhang, Zhe
    Wang, Shuai
    Yu, Sheng
    Wang, Qiming
    [J]. CLINICAL LUNG CANCER, 2019, 20 (05) : E548 - E551
  • [26] Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib
    Wang, Yan-li
    Wu, Zhen-zhen
    Zhang, Heng-rui
    Chen, Dong-sheng
    Zhao, Xin
    [J]. LUNG CANCER, 2021, 154 : 216 - 218
  • [27] Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib
    Xu, X.
    Li, N.
    Fan, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S445 - S445
  • [28] Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion
    Xinyi Lin
    Xiaojuan Yang
    Yuan Tan
    Qianqian Duan
    Mei He
    [J]. Investigational New Drugs, 2022, 40 : 1160 - 1163
  • [29] Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion
    Lin, Xinyi
    Yang, Xiaojuan
    Tan, Yuan
    Duan, Qianqian
    He, Mei
    [J]. INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1160 - 1163
  • [30] BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib
    Shan, Ling
    Jiang, Peidi
    Xu, Feng
    Zhang, Weilong
    Guo, Lei
    Wu, Jian
    Zeng, Yixin
    Jiao, Yuchen
    Ying, Jianming
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) : E37 - E39
12345